Business, Liquidity and Capital Resources (Details) - USD ($)		3 Months Ended		6 Months Ended
	Jan. 09, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Mar. 31, 2020	Dec. 31, 2019	Mar. 31, 2019	Dec. 31, 2018
Business, Liquidity and Capital Resources (Textual)
Cash and cash equivalents		$ 29,970,617		$ 29,970,617			$ 564,124
Net losses		(7,140,030)	$ (1,428,675)	(17,200,287)	$ (2,956,731)
Working capital		29,402,629		29,402,629
Stockholders' equity		59,430,533	1,999,852	59,430,533	1,999,852	$ 64,741,841	$ (2,127,959)	$ 3,326,065	$ 4,777,239
Net cash used in operating activities				(12,879,090)	(2,709,747)
Non stock based compensation		1,828,722	$ 102,462	4,626,529	$ 179,344
Net of offering costs		$ 39,600,000		$ 39,600,000
Reverse stock split, description	1-for-40			On January 9, 2020, in connection with, and prior to the completion of, the Merger, Protara Therapeutics, Inc. effected a 1-for-40 reverse stock split of its common stock, or the Reverse Stock Split, Private ArTara changed its name from "ArTara Therapeutics, Inc." to "ArTara Subsidiary, Inc.", and ArTara Therapeutics, Inc. changed its name from "Proteon Therapeutics, Inc." to "ArTara Therapeutics, Inc."
Private placement				$ 42,500,000